Gain From the Weight-Loss Trend With These Stocks
20:19 Share

Everyone’s been talking about the drug semaglutide, used to treat Type 2 diabetes. It’s marketed under the brand names Ozempic, Wegovy, and now, Mounjaro. Are any of the drugmakers a buy?

Salesforce’s Successful Quarter

HP is Having Problems

Macy’s Misses the Mark  

Diabetes Drugs Take Over

Biotech Frontrunners

Why is Pfizer Underperforming?

Semaglutide Risks

Biotech Stock Picks

What Higher Yields Mean for Retired ‘Bucket’ Investors

**Read about topics from this episode.  **

Salesforce Earnings: Margins Shine As New Signs of Pressure Remove Some Luster)

HP Earnings: Sales Remain Soft, Although Improvement Is on the Horizon; Shares Fairly Valued)

Macy’s Earnings: Lowered Outlook on Waning Spending Overshadows Positives; Shares Undervalued)

Novo Nordisk and Eli Lilly Lead Potential $60 Billion Obesity Drug Market; Valuations Look Rich)

Obesity Drug Stocks: Time to Buy?)

What to watch from Morningstar.

Double Trouble: How the Dot-Com and Tech Bubbles Compare)

What to Do as Recession Fears Grip Investors)

Just Where’s the U.S. Economy Headed?)

Active ETFs Take Off –– 3 Ideas for Investors)

Read what our team is writing:

Ruth Saldanha)

Karen Andersen)

Susan Dziubinski)

Christine Benz) 

Follow us on social media.

Ruth Saldanha on Twitter: @karishmaruth

Facebook: https://www.facebook.com/MorningstarInc/)

Twitter: https://twitter.com/MorningstarInc)

Instagram: https://www.instagram.com/morningstar)... 

LinkedIn: https://www.linkedin.com/company/5161/)